OneTrader | Monday, November 16, 2026 | US Stocks to Watch
Friday’s trading ended on a mixed note. The S&P 500 slipped 0.40% to 7,561.67, while the Dow Jones gained 0.10% to 52,347.55. The Nasdaq Composite declined 0.91%, reflecting renewed pressure on technology shares.
Today’s trading focus includes fresh quarterly results from Baidu, XPeng, Tyson Foods and Aramark, alongside takeover developments and important clinical-trial updates. Treasury yields, technology-sector weakness and company-specific guidance are likely to influence stock movements.
Previous Session Snapshot
| Index / Asset | Close | Change |
|---|---|---|
| S&P 500 | 7,561.67 | -0.40% |
| Dow Jones | 52,347.55 | +0.10% |
| Nasdaq Composite | 25,136.27 | -0.91% |
| Russell 2000 | 2,790.49 | -0.31% |
| VIX | 19.30 | +3.21% |
| US 10-year yield | 5.15% | +5 bps |
| Dollar Index (DXY) | 103.41 | +0.23% |
| WTI crude oil | $88.92 | +0.20% |
| Gold | $3,887.60 | +0.06% |
| Bitcoin | $68,185.63 | -4.43% |
In Simple Words
Wall Street enters Monday with technology stocks under pressure, while the Dow showed relative resilience in Friday’s session. Investors are balancing fresh corporate earnings, takeover developments and biotechnology trial results against elevated Treasury yields and uncertainty around growth stocks.
Also Read: US Top Earnings Today, November 16, 2026: Baidu, Tyson Foods, Aramark, XPeng and More
Stocks to Watch Today
| Company | Key development |
|---|---|
| TELUS (TU) | Québecor takeover proposal under review |
| XPeng (XPEV) | Q3 results and strong Q4 delivery outlook |
| Baidu (BIDU) | AI cloud growth offsets advertising weakness |
| Tyson Foods (TSN) | Q4 earnings and pressure on beef profitability |
| Aramark (ARMK) | Strong FY2026 results and higher shareholder returns |
| iQIYI (IQ) | Narrower losses despite falling revenue |
| Lexeo Therapeutics (LXEO) | Positive interim heart disease gene-therapy data |
| Alpha Tau Medical (DRTS) | Encouraging early brain cancer trial update |
| Summit Therapeutics (SMMT) | FDA rejection delays cancer drug approval |
| Aclaris Therapeutics (ACRS) | Phase 2 eczema trial misses primary endpoint |
1. TELUS (NYSE: TU)
TELUS confirmed that its board received an unsolicited, non-binding and conditional acquisition proposal from Québecor. An independent committee is reviewing the proposal alongside other strategic alternatives. The revised proposal includes an exchange ratio of 0.1600 to 0.1700 Québecor shares for each TELUS share, with the additional consideration representing approximately $0.77 per TELUS share. The stock was up around 26% in premarket trading at 8:05 AM ET.
Investors will watch whether the two companies can resolve regulatory, valuation and governance concerns. TELUS has highlighted potential regulatory difficulties and concerns about shareholders contributing most of the combined economic value while receiving minority voting rights. The special committee has not approved a transaction.
2. XPeng (NYSE: XPEV)
XPeng reported third-quarter revenue of RMB 24.28 billion, equivalent to approximately $3.62 billion, up 19.1% year over year. Vehicle deliveries reached 118,390 units, while gross margin stood at 18.9%. The company reported a net loss of RMB 870 million, compared with RMB 380 million in the year-ago quarter.
The company’s fourth-quarter outlook is a major focus. XPeng expects deliveries of 169,000 to 174,000 vehicles and revenue of RMB 30.4 billion to RMB 31.8 billion. Investors will assess whether higher deliveries can translate into better profitability without further pressure on margins.
3. Baidu (NASDAQ: BIDU)
Baidu reported third-quarter revenue of RMB 30.81 billion, down 1% year over year. Adjusted net income reached RMB 2.4 billion, while adjusted diluted earnings were RMB 6.78 per ADS. AI-linked business revenue increased 37% to RMB 13.2 billion, supported by a 94% jump in AI cloud infrastructure revenue to RMB 8.2 billion. However, online marketing revenue declined 22% to RMB 11.9 billion.
Investors will examine whether AI infrastructure can become a sustainable earnings driver as traditional advertising remains under pressure. Management’s commentary on AI spending, cloud demand, competition and the monetisation of its AI applications will be important for the stock.
4. Tyson Foods (NYSE: TSN)
Tyson Foods reported fourth-quarter fiscal 2026 sales of $14.59 billion, up 5.2% year over year. However, adjusted operating income declined 41% to $361 million, while adjusted earnings per share fell 47% to $0.61. The beef business remained a major pressure point, recording an adjusted operating loss of $171 million during the quarter.
Investors will focus on the company’s beef operations, livestock costs and margin recovery prospects. Performance across chicken and prepared foods will also matter as Tyson works to offset weakness in its beef segment.
5. Aramark (NYSE: ARMK)
Food and Facilities Services | Earnings and capital returns
Aramark reported fiscal 2026 revenue growth of 9%, while adjusted operating income increased 13% and adjusted EPS rose 21% to $2.23. Fourth-quarter adjusted EPS increased 25% to $0.71. The company also authorised a new $1 billion share repurchase programme and raised its quarterly dividend by 17%.
The company expects fiscal 2027 adjusted EPS growth of approximately 20% and organic revenue growth of 10%. Investors will watch whether new business wins, client retention and operating efficiencies support the outlook while maintaining its improving balance sheet.
6. iQIYI (NASDAQ: IQ)
iQIYI reported third-quarter revenue of RMB 6.01 billion, equivalent to approximately $896 million, down 10% year over year. Its operating loss narrowed to RMB 41.9 million from RMB 121.8 million a year earlier. The company also returned to non-GAAP operating profitability, reporting income of RMB 25 million compared with a loss in the corresponding period last year.
Investors will watch whether improving advertising revenue and lower content costs can support a sustained return to profitability. Subscriber engagement, content performance and the company’s transition towards an AI-supported video platform will remain important indicators.
7. Lexeo Therapeutics (NASDAQ: LXEO)
Lexeo reported encouraging interim results from its LX2020 gene-therapy programme targeting PKP2 arrhythmogenic cardiomyopathy, an inherited heart condition. Among seven high-dose participants, episodes of non-sustained ventricular tachycardia declined by an average of 80%. The company also said the FDA was open to considering this measure as the primary endpoint for a larger study.
The next focus is regulatory alignment and the design of a pivotal trial. Lexeo expects to initiate that study in the second half of 2027. Investors will also assess the durability of the treatment response, safety observations and the company’s available funding.
8. Alpha Tau Medical (NASDAQ: DRTS)
Alpha Tau Medical reported updated interim results from its REGAIN trial evaluating Alpha DaRT treatment for recurrent glioblastoma. All eight treated patients were alive as of November 11, while all six patients who had reached response assessment showed an objective response. Five recorded complete responses and one recorded a partial response.
The results are encouraging but remain early-stage clinical evidence. Investors will watch additional patient enrolment, longer-term survival data and follow-up scans. Radiation-related tissue changes also require further evaluation before the findings can support broader regulatory conclusions.
9. Summit Therapeutics (NASDAQ: SMMT)
Summit Therapeutics received an FDA Complete Response Letter for its biologics licence application covering ivonescimab combined with chemotherapy for certain patients with advanced non-small cell lung cancer. The FDA determined that the application did not establish sufficient evidence of effectiveness without a statistically significant improvement in overall survival.
Investors will focus on the company’s response to the regulatory setback, the possibility of additional clinical evidence and the revised timeline for the drug’s development. The decision creates uncertainty around the commercial launch prospects of a key programme.
10. Aclaris Therapeutics (NASDAQ: ACRS)
Aclaris Therapeutics announced that its Phase 2 ADMIRATION trial of bosakitug in moderate-to-severe atopic dermatitis failed to meet its primary and secondary endpoints. The company reported that the treatment achieved target engagement and reduced certain immune-activation biomarkers, but these findings did not translate into the required clinical trial outcomes.
Also Read: Stocks to Watch Today: November 13, 2026 | Oil India, HFCL, TruAlt Bioenergy and More
Investors will watch how the company reallocates resources towards its other development programmes, including modzatinib and ATI-052. Aclaris expects several clinical and regulatory milestones during 2027, making execution across its remaining pipeline particularly important.
What Investors Will Watch
Technology-sector sentiment: Weakness in semiconductor and growth stocks could influence the Nasdaq and broader market direction.
Investors should also monitor the November manufacturing survey and broader market participation as trading begins.
Disclaimer: This article is for educational and informational purposes only. Stocks mentioned are selected based on publicly reported developments and are not buy or sell recommendations. Investors should conduct their own research and consider their risk tolerance before making investment decisions.
Keep learning with OneTrader
Explore structured lessons and practical guides to build your market knowledge.

Need a laugh after all that money talk?
Paisa LOL: India's funniest finance page, with memes, comics, jokes and long funny stories.








